Last deal

$6.24M
Local Amount - CHF 6M

Amount

Post-IPO Equity

Stage

15.09.2022

Date

3

all rounds

$82.17M

Total amount

date founded

Financing round

General

About Company
Kuros Biosciences AG is a Swiss company that develops innovative products for tissue repair and regeneration.

Industry

Sector :

Subsector :

Also Known As

Cytos Biotechnology

founded date

01.01.2000

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Founded in 2000 as a spin-off of ETHZ, Kuros has a pipeline of products based on its proprietary technology platforms, developed in collaboration with ETHZ, the University of Zürich, and CalTech. In 2017, Kuros acquired Xpand Biotechnology to gain access to their MagnetOs bone graft substitutes. With one product already approved in the EU and US, and another expected to achieve EU approval this year, Kuros has attractive commercial prospects. They also have a second product, Neuroseal, under review for CE marking. Additionally, Kuros has a pipeline of clinical stage programs and has generated promising data in various indications and applications in the field of orthobiologics.
Contacts
Similar Companies
1000
Bonus BioGroup

Bonus BioGroup

Bonus BioGroup is a biotechnology company that supplies tissue-regenerating viable bone grafts.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Haifa, Israel
Biologics 4 Life

Biologics 4 Life

Biologics 4 Life is an early-stage orthobiologics company developing patented biomaterials for bone regeneration.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical Device

Location

Pertuis, France

total rounds

1
BioD, LLC

BioD, LLC

BioD, LLC is a biotech company that develops and commercializes regenerative medicine products derived from placental tissues.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Cordova, Memphis, TN, USA
MiMedx Group

MiMedx Group

MiMedx Group is a biopharmaceutical company that develops and markets regenerative biologics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Marietta, GA, USA

total rounds

7

total raised

$266.36M

Financials

Funding Rounds
9
3

Number of Funding Rounds

$82.17M

Money Raised

Their latest funding was raised on 15.09.2022. Their latest investor Optiverder. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
15.09.2022
2
$6.24M
Local Amount - CHF 6M
09.04.2019
1
$5M
Local Amount - CHF 5M
19.12.2018
$16.2M
Local Amount - CHF 16.1M

Optiverder

Investment vehicle

Location

Delft, Netherlands

count Of Investments

3

Alpha Capital AG

Alpha Capital AG is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance, Venture Capital

count Of Investments

1
Nice & Green SA

Nice & Green SA

Nice & Green Corporate Finance Services provides growth finance to small and mid-sized listed companies.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Finance

Location

Nyon, Switzerland

count Of Investments

28

count Of Exists

4
Co-Investors
Investors
14
6

Number of lead investors

14

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Equity
Yes
Post-IPO Equity
Yes
Post-IPO Equity

Optiverder

Investment vehicle

Location

Delft, Netherlands

count Of Investments

3
Nice & Green SA

Nice & Green SA

Nice & Green Corporate Finance Services provides growth finance to small and mid-sized listed companies.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Finance

Location

Nyon, Switzerland

count Of Investments

28

count Of Exists

4

Alpha Capital AG

Alpha Capital AG is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance, Venture Capital

count Of Investments

1
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Xpand Biotechnology acquired by Kuros Biosciences

Xpand Biotechnology acquired by Kuros Biosciences

acquirer

Kuros Biosciences
Kuros Biosciences

date

19.12.2016

type

Acquisition
Xpand Biotechnology

Xpand Biotechnology

Xpand Biotechnology develops proprietary surface science technology for bone repair and regeneration.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Manufacturing, Life Science

Location

Bilthoven, Netherlands

total rounds

1

total raised

$2.03M

People

Founders
1
Jeffrey A. Hubbell
Jeffrey A. Hubbell

Jeffrey A. Hubbell

Jeff is a professor and founder of the Institute of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne (Swiss Federal Institute of Technology, EPFL), and a professor at the Institute of Molecular Engineering at the University of Chicago. His research focuses on engineering approaches to immunomodulation, drug delivery, and regenerative medicine. Jeff has successfully spun-out several companies based on technology from his laboratories, co-founding Focal, Inc. (Lexington, MA) and founding Kuros Biosurgery AG (Zurich, Switzerland). He is a fellow of the American Institute of Medical and Biological Engineering and a Member of the National Academy of Engineering.

current job

Anokion
Anokion

organization founded

4

Jeffrey A. Hubbell

Employee Profiles
9

Chris Fair

Chief Operating Officer

Kyle Altier

Kyle Altier

Regional Sales Manager at Kuros Biosciences

Marco Boorsma

Marco Boorsma

Project Manager and Scientist

Didier Cowling

CEO

Jason Schense

CTO

Harry Welten

Harry Welten

Chief Financial Officer

Jeffrey A. Hubbell

Jeffrey A. Hubbell

Founder

Sebastian Meyer

Sebastian Meyer

Group Leader

Activity

Recent News
8
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week